Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 7Uterine Cervical Neoplasms 5Neoplasms 4Esophageal Neoplasms 4Brain Neoplasms 4Thyroid Neoplasms 3Neuroendocrine Tumors 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Testicular Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Carcinoma, Transitional Cell 2Astrocytoma 2Adrenal Gland Neoplasms 2Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

romidepsin 12Cyclophosphamide 10fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 7Gemcitabine 7Bortezomib 7fludarabine 6Lenalidomide 6Filgrastim 6tanespimycin 5Vorinostat 5Magnetic Resonance Spectroscopy 5Etoposide 5Biopsy 5belinostat 4Tacrolimus 4Depsipeptides 4Brentuximab Vedotin 4Whole-Body Irradiation 3Specimen Handling 3Radiotherapy 3Oxaliplatin 3Nivolumab 3Methylprednisolone 3Lactones 3Irinotecan 3Ipilimumab 3Doxorubicin 3Dexamethasone 3Dasatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell, Cutaneous × Fluorodeoxyglucose F18 × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡